Safety and Pharmacokinetics of Iotrolan in Hysterosalpingography

Authors:
  • TTTaichi Tsujimoto
    Taichi Tsujimoto
  • KIKatsumi Iwai
    Katsumi Iwai
  • KIKozue Ishida
    Kozue Ishida
  • RURyoko Uchimoto
    Ryoko Uchimoto
  • TMTomoaki Miyazawa
    Tomoaki Miyazawa
  • HAHaruyoshi Azuma
    Haruyoshi Azuma

Abstract
The authors compared the safety and pharmacokinetics of Iotrolan (water-soluble) in hysterosalpingography (HSG) with those of Lipiodol (oil-soluble). Iotrolan and Lipiodol were administered intraperitoneally at doses of 100 mg iodine/kg to female rabbits. Retention in the body was investigated by x-ray imaging, plasma kinetics, and urinary and fecal excretion. Irritability in the abdomen was investigated by histologic examination. Iotrolan was entirely excreted into the urine within 2 days after administration. Conversely, Lipiodol was excreted into the urine, had a half-life of 50 days, and was retained for more than 21 days in the abdomen. Iotrolan induced no inflammatory reaction in the abdomen, whereas Lipiodol induced a marked abdominal inflammatory reaction, including granuloma formation. Iotrolan had no effect on iodine concentration in the thyroid; Lipiodol increased iodine concentration significantly. Iotrolan, which is a water-soluble and nonionic dimeric contrast medium, has potential greater safety for use in HSG than Lipiodol.